

**Virginia Medicaid Preferred Drug List (PDL) Program:
Annual Review of PDL Phase II and Review of New Drugs & New Drug Classes
Pharmacy and Therapeutics Committee Meeting
Thursday, March 30, 2006
9:00 a.m., DMAS Board Room
REVISED DRAFT AGENDA**

**Welcome and Comments from
DMAS' Director**

**Patrick Finnerty, DMAS
Director**

**Update on Pharmacy Medicaid
Reform Initiatives**

**Patrick Finnerty, DMAS
Director**

Comments from the Chairperson

**Randy Axelrod, M.D.,
Chairman**

**Acceptance of Minutes From
October 31, 2005 P&T Meeting**

P&T Committee Members

Drug Class Discussions

P&T Committee Members

Review of New Drugs in PDL Phase I

- Xopenex HFA - Beta Adrenergic

Phase II PDL Annual Review

- Oral Hypoglycemics
 - Second Generation
 - Sulfonylureas
 - Alpha-Glucosidase Inhibitors
 - Biguanides
 - Biguanide Combination Products
 - Meglitinides
 - Thiazolidinediones (TZDs)
- Leukotriene Modifiers
- Non-Steroidal Anti- Inflammatory Drugs (NSAID)
- Serotonin Receptor Agonists (Triptans)
- Oral Antifungals for Onychomycosis
- Bisphosphonates for Osteoporosis
- Second Generation Cephalosporins (Antibiotics)
- Third Generation Cephalosporins (Antibiotics)
- Second Generation Quinolones – Systemic (Antibiotics)
- Third Generation Quinolones – Systemic (Antibiotics)
- Macrolides - Adult and Pediatric (Antibiotics)
- Antihyperkinesia/CNS Stimulants (Medications for ADD/ADHD)
- Alpha-2 Adrenergic - Ophthalmic
- Beta-blockers -Ophthalmic
- Carbonic Anhydrase Inhibitors- Ophthalmic
- Prostaglandin Inhibitors - Ophthalmic
- Long Acting Narcotics

Review of New Drug Classes for PDL Eligibility*

P&T Committee Members

- Ophthalmic Anti-Inflammatory
- Ophthalmic Quinolones
- Ophthalmic Antihistamines
- Ophthalmic Mast Cell Stabilizers
- Herpes Antivirals
- Influenza

Confidential Meeting

Confidential Meeting for P&T Committee Members, DMAS, and FHSC Pursuant to 42 U.S.C. § 1396r-8 to discuss pricing information

Criteria Discussion of Phase I New Drugs

P&T Committee Members

Criteria Discussions for PDL Phase II and New* Drug Classes

P&T Committee Members

Next Meeting – June 2006

**Randy Axelrod, M.D.,
Chairman**

**Criteria discussions will be held for classes only if deemed PDL eligible by the P&T Committee during Drug Class Discussions*